Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) has earned an average rating of “Buy” from the eight analysts that are currently covering the firm, Marketbeat reports. Eight research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $9.00.
Several brokerages have recently issued reports on PYXS. Stifel Nicolaus assumed coverage on Pyxis Oncology in a research note on Thursday, August 8th. They issued a “buy” rating and a $10.00 price objective for the company. Jefferies Financial Group reissued a “buy” rating and issued a $10.00 price objective on shares of Pyxis Oncology in a research report on Tuesday, May 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Pyxis Oncology in a research report on Friday, August 16th.
Read Our Latest Stock Report on PYXS
Hedge Funds Weigh In On Pyxis Oncology
Pyxis Oncology Stock Down 9.2 %
NASDAQ:PYXS opened at $3.44 on Wednesday. Pyxis Oncology has a 52 week low of $1.35 and a 52 week high of $6.85. The company has a market cap of $202.57 million, a price-to-earnings ratio of -2.53 and a beta of 1.29. The company has a fifty day simple moving average of $3.43 and a two-hundred day simple moving average of $4.16.
Pyxis Oncology Company Profile
Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.
See Also
- Five stocks we like better than Pyxis Oncology
- Investing in Construction Stocks
- 3 Small Cap Stocks That Insiders Are Buying
- Quiet Period Expirations Explained
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- The How and Why of Investing in Gold Stocks
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.